Table 1.

Association of anti-ANO2 antibody levels with disease

Sample cohort	Cases (n)	Controls (n)	Beta	P	P*
Initial	1,040	1,058	428	5.0 × 10−13	6.9 × 10−21
Validation	7,603	6,170	182	7.1 × 10−12	2.3 × 10−22
Whole	8,746	7,228	213	4.2 × 10−27	3.5 × 10−36
Pre-MS	476	478	−80	0.42	0.23
RA	986	689	−2	0.95	0.38
IIM	219	306**	4	0.79	0.81
SLE	349	306**	−2	0.85	0.36

Association analyses were adjusted for age, sex, and EBNA1 status. Analyses were also adjusted for study type for the validation and whole cohorts. *Log₁₀ transformed signal intensities. **Same control set (selected to match SLE cases) were used for both IIM and SLE cohorts. MS, multiple sclerosis; RA, rheumatoid arthritis; IIM, idiopathic inflammatory myopathy; SLE, systemic lupus erythematosus.